228 related articles for article (PubMed ID: 19965843)
21. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection.
Bremell D; Mattsson N; Edsbagge M; Blennow K; Andreasson U; Wikkelsö C; Zetterberg H; Hagberg L
BMC Neurol; 2013 Jan; 13():2. PubMed ID: 23294475
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic relevance of the chemokine CXCL13 and anti-C6 peptide antibodies in patients with neuroborreliosis].
Pícha D; Moravcová L; Smíšková D
Epidemiol Mikrobiol Imunol; 2017; 66(2):80-85. PubMed ID: 28691831
[TBL] [Abstract][Full Text] [Related]
23. [CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine].
Rupprecht TA; Lechner C; Tumani H; Fingerle V
Nervenarzt; 2014 Apr; 85(4):459-64. PubMed ID: 24682168
[TBL] [Abstract][Full Text] [Related]
24. A prospective study on the role of CXCL13 in Lyme neuroborreliosis.
Schmidt C; Plate A; Angele B; Pfister HW; Wick M; Koedel U; Rupprecht TA
Neurology; 2011 Mar; 76(12):1051-8. PubMed ID: 21422457
[TBL] [Abstract][Full Text] [Related]
25. The recomBead Borrelia antibody index, CXCL13 and total IgM index for laboratory diagnosis of Lyme neuroborreliosis in children.
Skogman BH; Lager M; Henningsson AJ; Tjernberg I
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2221-2229. PubMed ID: 28730535
[TBL] [Abstract][Full Text] [Related]
26. Prospective study on the chemokine CXCL13 in neuroborreliosis and other aseptic neuroinfections.
Pícha D; Moravcová L; Smíšková D
J Neurol Sci; 2016 Sep; 368():214-20. PubMed ID: 27538636
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of two assays for CXCL13 analysis in cerebrospinal fluid for laboratory diagnosis of Lyme neuroborreliosis.
Henningsson AJ; Gyllemark P; Lager M; Skogman BH; Tjernberg I
APMIS; 2016 Nov; 124(11):985-990. PubMed ID: 27651242
[TBL] [Abstract][Full Text] [Related]
28. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response.
Leypoldt F; Höftberger R; Titulaer MJ; Armangue T; Gresa-Arribas N; Jahn H; Rostásy K; Schlumberger W; Meyer T; Wandinger KP; Rosenfeld MR; Graus F; Dalmau J
JAMA Neurol; 2015 Feb; 72(2):180-6. PubMed ID: 25436993
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid chemokine CXCL13 in the diagnosis of neuroborreliosis in children.
Sillanpää H; Skogman BH; Sarvas H; Seppälä IJ; Lahdenne P
Scand J Infect Dis; 2013 Jul; 45(7):526-30. PubMed ID: 23521134
[TBL] [Abstract][Full Text] [Related]
30. CXCL13 may improve diagnosis in early neuroborreliosis with atypical laboratory findings.
Borde JP; Meier S; Fingerle V; Klier C; Hübner J; Kern WV
BMC Infect Dis; 2012 Dec; 12():344. PubMed ID: 23228054
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid CXCL13 in non-borrelial central nervous system infections: contribution of CXCL13 to the differential diagnosis.
Smíšková D; Džupová O; Moravcová L; Pícha D
Infect Dis (Lond); 2023 Aug; 55(8):551-558. PubMed ID: 37317698
[TBL] [Abstract][Full Text] [Related]
32. Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis.
Ziegler K; Rath A; Schoerner C; Meyer R; Bertsch T; Erbguth F; Bogdan C; Steinmann J; Held J
J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32434781
[TBL] [Abstract][Full Text] [Related]
33. [CXCL-13 as a biomarker in the diagnostics of neuroborreliosis].
Waiß C; Kindler W; Ströbele B; Aspöck C; Oberndorfer S
Nervenarzt; 2017 Jun; 88(6):635-641. PubMed ID: 28184973
[TBL] [Abstract][Full Text] [Related]
34. Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2.
Rupprecht TA; Kirschning CJ; Popp B; Kastenbauer S; Fingerle V; Pfister HW; Koedel U
Infect Immun; 2007 Sep; 75(9):4351-6. PubMed ID: 17562761
[TBL] [Abstract][Full Text] [Related]
35. The predictive value of CXCL13 in suspected Lyme neuroborreliosis: a retrospective cross-sectional study.
Knudtzen FC; Nilsson AC; Hovius JW; Skarphedinsson S
Eur J Clin Microbiol Infect Dis; 2020 Aug; 39(8):1461-1470. PubMed ID: 32172371
[TBL] [Abstract][Full Text] [Related]
36. Chemokine CXC Ligand 13 in Cerebrospinal Fluid Can Be Used as an Early Diagnostic Biomarker for Lyme Neuroborreliosis: A Meta-Analysis.
Yang J; Han X; Liu A; Bao F; Peng Y; Tao L; Ma M; Bai R; Dai X
J Interferon Cytokine Res; 2017 Oct; 37(10):433-439. PubMed ID: 28972436
[TBL] [Abstract][Full Text] [Related]
37. Neuroimmunomodulators in Neuroborreliosis and Lyme Encephalopathy.
Eckman EA; Pacheco-Quinto J; Herdt AR; Halperin JJ
Clin Infect Dis; 2018 Jun; 67(1):80-88. PubMed ID: 29340592
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity and specificity of cerebrospinal fluid CXCL13 for diagnosing Lyme neuroborreliosis - a study on 1410 patients and review of the literature.
Lintner H; Hochgatterer-Rechberger P; Pischinger B; Seier J; Vollmann P; Haushofer A; Rittner H; Sommer C; Topakian R
J Neurol Sci; 2020 Jul; 414():116843. PubMed ID: 32344220
[TBL] [Abstract][Full Text] [Related]
39. [New biomarker discovered. Will the diagnosis of neuroborreliosis soon be easier (interview by Maria Weiss)?].
Rupprecht T
MMW Fortschr Med; 2009 Apr; 151(18):8. PubMed ID: 19769063
[No Abstract] [Full Text] [Related]
40. Point-of-care testing for CXCL13 in Lyme neuroborreliosis.
Pietikäinen A; Oksi J; Hytönen J
Diagn Microbiol Infect Dis; 2018 Jul; 91(3):226-228. PubMed ID: 29567125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
